Cancer is one of the world’s most pressing health care challenges. On the whole, research progress from one year to the next is incremental, and true breakthroughs are exceptional. Nevertheless, every year brings new knowledge and insights that help direct further research and ultimately improve the outlook for patients with cancer. Clinical Cancer Advances 2017 highlights the most important clinical advances of the past year and previews where cancer science is headed. Advances highlighted
As of December 2016, there are now TWO patient advocates on the NCI Renal Task Force.
The US National Cancer Institute’s Renal Task Force is an advisory group that involves the renal oncology community to address the design and prioritization of NCI funded phase 2 and phase 3 clinical trials in renal cell cancer.
Deb Maskens joins the Task Force as a Patient Advocate from the IKCC (International Kidney
by Susan Poteat and Hans Hammers, M.D.
KCCure is pleased to announce an inaugural Request for Applications for a $100,000 Grant Award to fund innovative high-risk, high-impact ideas for kidney cancer research. The application deadline is March 15, 2017. The grant will be awarded in April 2017, and funding will cover a research project for a two year period. Investigators representing academic research centers within the United States are eligible to apply.
Proposed projects should develop
by Deb Maskens, Kidney Cancer Canada
The American Society of Clinical Oncology (ASCO) held its annual Genitourinary (GU) Cancers Symposium in San Francisco from January 7-9.
The theme of this year’s Symposium was “Patient-Centric Care: Translating Research to Results”. The program included localized and advanced disease, immunotherapy and health care outcomes. The program was bursting with kidney cancer content including 19 presentations, 129 posters and 2 evening ancillary meetings. It was
IKCC launches an educational website for immuno-oncology for kidney cancer. Powerful Patient interviews Deb Maskens about this effort and its goals.
Dr. Eamonn Maher is heading an effort in the UK to identify new genetic causes of inherited kidney cancer.